{
  "input": {
    "mode": "execute_actions",
    "query": {
      "entity": "Generalised pustular psoriasis",
      "relation": "indication"
    },
    "items": [
      {
        "hypothesis_id": "H1",
        "graph_actions": [
          {
            "type": "stress_test_safety",
            "topic": "Adalimumab adverse effects",
            "expectation": "检验非特异性靶点风险对疗效的潜在限制",
            "assignee": "Skeptic"
          }
        ]
      },
      {
        "hypothesis_id": "H2",
        "graph_actions": [
          {
            "type": "stress_test_safety",
            "topic": "Etanercept adverse effects",
            "expectation": "评估潜在的不良反应对Etanercept治疗效果的影响",
            "assignee": "Skeptic"
          }
        ]
      }
    ],
    "tegraph_snapshot": {
      "nodes": [
        {
          "id": "drug_adalimumab",
          "type": "Drug",
          "label": "Adalimumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_etanercept",
          "type": "Drug",
          "label": "Etanercept",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_infliximab",
          "type": "Drug",
          "label": "Infliximab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_secukinumab",
          "type": "Drug",
          "label": "Secukinumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_ustekinumab",
          "type": "Drug",
          "label": "Ustekinumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_brodalumab",
          "type": "Drug",
          "label": "Brodalumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_tildrakizumab",
          "type": "Drug",
          "label": "Tildrakizumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_guselkumab",
          "type": "Drug",
          "label": "Guselkumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_apremilast",
          "type": "Drug",
          "label": "Apremilast",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_methotrexate",
          "type": "Drug",
          "label": "Methotrexate",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_cyclosporine",
          "type": "Drug",
          "label": "Cyclosporine",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_acitretin",
          "type": "Drug",
          "label": "Acitretin",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "target_tnf_alpha",
          "type": "Target",
          "label": "TNF-α",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "pathway_inflammation",
          "type": "Pathway",
          "label": "Inflammation Pathway",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "disease_generalised_pustular_psoriasis",
          "type": "Disease",
          "label": "Generalised Pustular Psoriasis",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_ot_adalimumab",
          "type": "Target",
          "label": "Off-target Adalimumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rp_adalimumab",
          "type": "Pathway",
          "label": "Risk Pathway Adalimumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adv_adalimumab",
          "type": "Phenotype",
          "label": "Adverse Phenotype Adalimumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "H1",
          "type": "Hypothesis",
          "label": "Adalimumab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H2",
          "type": "Hypothesis",
          "label": "Etanercept",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H3",
          "type": "Hypothesis",
          "label": "Infliximab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H4",
          "type": "Hypothesis",
          "label": "Secukinumab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H5",
          "type": "Hypothesis",
          "label": "Ustekinumab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H6",
          "type": "Hypothesis",
          "label": "Brodalumab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H7",
          "type": "Hypothesis",
          "label": "Tildrakizumab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H8",
          "type": "Hypothesis",
          "label": "Guselkumab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H9",
          "type": "Hypothesis",
          "label": "Apremilast",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H10",
          "type": "Hypothesis",
          "label": "Methotrexate",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H11",
          "type": "Hypothesis",
          "label": "Cyclosporine",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H12",
          "type": "Hypothesis",
          "label": "Acitretin",
          "attrs": {
            "agent": "PI"
          }
        }
      ],
      "edges": [
        {
          "source": "drug_adalimumab",
          "target": "target_tnf_alpha",
          "relation": "acts_on",
          "weight": 0.9,
          "agent": "Proponent",
          "rationale": "抗TNF-α药物，常用于化脓性脓疱型银屑病"
        },
        {
          "source": "drug_etanercept",
          "target": "target_tnf_alpha",
          "relation": "acts_on",
          "weight": 0.9,
          "agent": "Proponent",
          "rationale": "抗TNF-α药物，已知对该病有效"
        },
        {
          "source": "drug_infliximab",
          "target": "target_tnf_alpha",
          "relation": "acts_on",
          "weight": 0.9,
          "agent": "Proponent",
          "rationale": "抗TNF-α药物，能改善皮肤症状"
        },
        {
          "source": "drug_secukinumab",
          "target": "target_tnf_alpha",
          "relation": "modulates",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "可通过干扰炎症通路影响该病"
        },
        {
          "source": "drug_ustekinumab",
          "target": "target_tnf_alpha",
          "relation": "modulates",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "作用于IL-12与IL-23通路，降低炎症"
        },
        {
          "source": "drug_brodalumab",
          "target": "target_tnf_alpha",
          "relation": "modulates",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "通过抑制IL-17通路减轻症状"
        },
        {
          "source": "drug_tildrakizumab",
          "target": "target_tnf_alpha",
          "relation": "modulates",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "通过作用于IL-23途径改善症状"
        },
        {
          "source": "drug_guselkumab",
          "target": "target_tnf_alpha",
          "relation": "modulates",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "通过调节炎症反应，改善相关症状"
        },
        {
          "source": "drug_apremilast",
          "target": "pathway_inflammation",
          "relation": "modulates",
          "weight": 0.6,
          "agent": "Proponent",
          "rationale": "通过PDE4抑制作用降低炎症"
        },
        {
          "source": "drug_methotrexate",
          "target": "pathway_inflammation",
          "relation": "inhibits",
          "weight": 0.6,
          "agent": "Proponent",
          "rationale": "抑制免疫反应，可能改善症状"
        },
        {
          "source": "drug_cyclosporine",
          "target": "pathway_inflammation",
          "relation": "inhibits",
          "weight": 0.6,
          "agent": "Proponent",
          "rationale": "免疫抑制，可能对病情有促进作用"
        },
        {
          "source": "drug_acitretin",
          "target": "pathway_inflammation",
          "relation": "modulates",
          "weight": 0.5,
          "agent": "Proponent",
          "rationale": "可通过调节角质形成细胞作用改善病情"
        },
        {
          "source": "target_tnf_alpha",
          "target": "pathway_inflammation",
          "relation": "involved_in",
          "weight": 0.9,
          "agent": "Proponent",
          "rationale": "TNF-α在炎症通路中的关键作用"
        },
        {
          "source": "pathway_inflammation",
          "target": "disease_generalised_pustular_psoriasis",
          "relation": "causes",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "炎症反应与该疾病密切相关"
        },
        {
          "source": "drug_adalimumab",
          "target": "n_ot_adalimumab",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能非特异性靶点影响"
        },
        {
          "source": "n_ot_adalimumab",
          "target": "n_rp_adalimumab",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "潜在风险通路确立"
        },
        {
          "source": "n_rp_adalimumab",
          "target": "n_adv_adalimumab",
          "relation": "causes",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可导致不良表型"
        },
        {
          "source": "n_adv_adalimumab",
          "target": "H1",
          "relation": "refutes",
          "weight": 0.8,
          "agent": "Skeptic",
          "rationale": "若此风险成立，药效可能受限"
        }
      ],
      "round_index": 2
    },
    "constraints": {
      "max_new_nodes": 50,
      "max_new_edges": 64,
      "batched": true
    },
    "ablation_config": {
      "enable_debate": true,
      "enable_skeptic": true,
      "enable_pi_interrupts": true,
      "enable_textual_feedback": true,
      "enable_heuristic_transfer": true,
      "enable_seed_regen": true,
      "weights": {
        "path_disjointness": 1.0
      },
      "mode": "graph"
    }
  },
  "output": {
    "hypothesis_id": "H1",
    "executed_actions": [
      {
        "action_ref": 0,
        "status": "done",
        "graph_updates": {
          "add_nodes": [],
          "add_edges": [],
          "merge": [],
          "set_weights": [],
          "conflict_hotspots": [
            {
              "topic": "Adalimumab adverse effects",
              "pro_nodes": [
                "drug_adalimumab"
              ],
              "con_nodes": [
                "n_rp_adalimumab",
                "n_adv_adalimumab"
              ],
              "note": "非特异性靶点引发不良反应可能影响疗效"
            }
          ]
        },
        "notes": "已完成针对Adalimumab的不良反应的安全性压力测试。"
      }
    ],
    "unexecuted_actions": [],
    "residual_conflicts": []
  }
}